J&J faces trial in $1B Risperdal influence case

A Texas jury is set to consider allegations that Johnson & Johnson's Janssen unit used false advertising, grants, junkets and other perks to persuade state officials to give its Risperdal antipsychotic drug preferential treatment in a protocol for treating psychiatric disorders. The company faces a potential $1 billion in liability. Report | Article

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.